Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Infusion Rate + Cisplatin in NSCLC
NCT00191620Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2004
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of gemcitabine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Objective Response Rate. Started Mar 2004; status: completed.
02
Drugs
gemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00191620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191620.